Valencia

• Study of durvalumab or placebo administered with radiation therapy for patients with early stage non-small cell lung cancer Study of osime … Ended recruitment
  2024-512667-31-00 5 2019-04-23 Main cohort: Patients with unresected Stage I/II, lymph-node negative
• Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended recruitment
  2023-507564-39-00 1 2019-03-11 Patients with Advanced Solid Tumors
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer Ended recruitment
  2023-506890-37-00 1 2019-03-01 "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"
• A study to test IMGN632 in adults with CD123-positive Acute Myeloid Leukemia and other CD123 positive Hematologic cancers. Ended recruitment
  2024-514195-40-00 7 2019-02-28 Acute Myeloid Leukemia and other blood cancers
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll … Ended recruitment
  2023-509602-29-00 5 2019-02-11 Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
• Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended recruitment
  2023-505495-30-00 5 2019-02-01 Immunoglobulin A Nephropathy (IgAN)
• DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Ended recruitment
  2024-513867-19-00 5 2019-01-31 metastatic Castration-Resistant Prostate Cancer (mCRPC)
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma … Ended recruitment
  2022-502937-24-00 5 2019-01-02 Atopic Dermatitis
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended recruitment
  2023-506921-12-00 5 2018-12-27 ER+/HER2- Breast Cancer
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter … Ended recruitment
  2022-501485-22-00 5 2018-12-18 Myelodysplastic syndrome (MDS)
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat … Ended recruitment
  2024-513912-89-00 10 2018-12-13 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
• An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Participants with … Ended recruitment
  2023-508463-71-00 5 2018-11-30 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended recruitment
  2022-501817-29-00 5 2018-11-27 High Risk Non-muscle invasive bladder cancer
• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year … Ended recruitment
  2024-516905-22-00 5 2018-10-22 Multiple myeloma
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi … Ended recruitment
  2024-510967-41-00 5 2018-09-21 Metastatic colorectal cancer
• A global study to assess the effects of Osimertinib following chemoradiation in patients with Stage III unresectable non-small cell lung can … Ended recruitment
  2022-500860-36-00 5 2018-09-19 Histologically documented non-small cell lung cancer of predominantly
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended recruitment
  2024-513206-65-00 5 2018-08-10 resected squamous cell carcinoma of head and neck
• A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re … Ended recruitment
  2023-506861-76-00 5 2018-08-09 Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplasti
• Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos … Ended recruitment
  2023-505341-23-00 5 2018-07-27 Non-muscle invasive bladder cancer

Showing 1,369–1,392 of 1,853 trials